查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008444

药物动力学服务市场：按类型、服务类型和最终用户划分－2026-2032年全球预测

Pharmacokinetics Services Market by Type, Service Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年药物动力学服务市场价值 13 亿美元，预计到 2026 年将成长至 14.1 亿美元，复合年增长率为 9.34%，到 2032 年将达到 24.3 亿美元。

主要市场统计数据
基准年 2025 13亿美元
预计年份：2026年 14.1亿美元
预测年份 2032 24.3亿美元
复合年增长率 (%) 9.34%

概述药物动力学服务调查方法在现代药物发现的基础和策略重要性。

药物动力学服务是现代药物发现和开发的重要支柱，它提供了将分子特性与临床结果联繫起来的定量基础。本导言将药物动力学定位为交叉学科领域，它整合了分析化学、生物分析、建模和体内实验，以阐明药物的吸收、分布、代谢和排泄过程。透过了解候选药物在生物系统中的行为，药物动力学指导临床前和临床给药策略、安全性评估以及转化决策。

技术进步、治疗方法多样化以及监管期望的变化正在重塑医疗服务提供者的能力和科学合作的性质。

受技术进步、治疗方法转变和监管要求变化的驱动，药物动力学服务领域正经历着变革性的转变。生物分析仪器的创新，例如质谱灵敏度的提高和样品处理的自动化，正在缩短检测週期并扩大可可靠定量分析的化合物范围。同时，生物製药、基因疗法和核酸药物的兴起，迫使服务供应商开发与标准小分子工作流程显着不同的专用检测方法和基质处理能力。

由于 2025 年关税变化给供应链带来了越来越大的压力，并增加了跨境复杂性，业务永续营运和筹资策略变得越来越重要。

2025年美国关税政策和贸易趋势的变化将对药物动力学服务生态系统产生多方面的影响，主要体现在供应链和成本管道方面，而非直接的科学影响。许多服务供应商依赖进口原料、特殊试剂和昂贵的设备零件。这些投入品关税的增加可能会增加采购的复杂性，并促使企业重新评估筹资策略。为此，各机构可能会考虑增加库存缓衝、认证替代供应商或转向区域采购网络，以维持营运的连续性。

基于细分的详细洞察，揭示了每种产品类型、服务方法和客户画像的不同分析需求和交付模式。

细分市场分析揭示了跨产品类型、服务形式和最终用户类别的服务开发和客户参与路径清晰可见。按类型划分，市场被分为“高分子量药物动力学服务”和“低分子量药物动力学服务”，突显了二者不同的分析需求。高分子量药物动力学需要开发免疫检测、配体结合分析以及专门的样品处理方法来解决稳定性和基质效应问题，而低分子量药物动力学通常采用高分辨率质谱和经验证的层析法。基于服务类型，市场进一步细分为“体外”和“体内”，表明体外ADME和稳定性测试通过提供早期候选化合物筛选和了解清除途径机制的信息，对体内药物动力学研究起到了补充作用。市场分析按最终用户细分，重点关注学术和政府研究机构、生物技术公司、受託研究机构(CRO) 和製药公司，表明客户需求范围从探索性和假设主导的研究到完全符合 GLP（良好实验室规范）的研究，涉及监管申报所需的全面文件。

区域竞争优势和营运考量有助于药物动力学服务供应商确定在全球何处投资、合作和拓展业务。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太地区的服务提供、基础设施投资和合作网络，每个地区都有其独特的竞争优势和营运考量。在美洲，生物技术中心和临床开发中心的集中分布有利于快速转化工作流程和医患密切合作，而监管路径和支付方环境则影响着北美申办者对临床药理学和资料包的关注。在欧洲、中东和非洲，法规环境的多样性以及与学术和研究机构的紧密合作促进了跨境合作、多中心试验以及研究方法的统一检验，以满足不同司法管辖区的要求。

在竞争激烈的环境中，那些整合先进分析技术、跨学科专业知识和以客户为中心的经营模式，并建立长期伙伴关係的供应商具有优势。

药物动力学服务领域的主要企业已从提供简单检测的交易型服务发展成为提供涵盖生物分析、建模和法规支援的综合性科学伙伴关係的企业。成功的企业透过投资平台自动化、数据完整性系统以及跨职能团队来脱颖而出，这些团队能够将分析结果转化为可操作的药物动力学和动态解读。与仪器製造商和软体供应商建立策略合作伙伴关係可以提高分析灵敏度和处理能力，而内部开发的标准化报告范本则可以加快法规申报和客户决策速度。

服务供应商增强科学研究能力、营运韧性和以客户为中心的商业性框架的实际策略重点。

产业领导企业应优先考虑能够提升短期内科研能力、营运韧性和客户协作的切实可行的转型措施。首先，投资于平台自动化和稳健的生物分析工作流程将有助于缩短週转时间并提高结果的可重复性，这对于在日益多元化的治疗方法保持竞争力至关重要。其次，拓展服务团队的建模和模拟专业知识将使供应商能够提供预测性见解，从而辅助剂量选择和试验设计，进而为客户的专案增添战略价值。

采用透明、多方面的研究途径，结合专家访谈、文献整合和情境分析，检验药物动力学服务的趋势和影响。

本分析的调查方法融合了定性专家访谈、专业文献综述以及对技术和监管趋势的系统评估。关键见解来自与药物动力学专家、临床药理学家、实验室管理人员和采购专家的对话，从而确保对各项技术的能力和局限性有全面的了解。辅助研究包括同行评审文章、监管指导文件和近期技术白皮书，以反映生物分析仪器、建模技术和检测验证实践的最新进展。

概述药物动力学服务提供者在协调科学创新、营运韧性和以客户为中心的服务交付方面面临的策略挑战。

总之，药物动力学服务在将分子层面的发现转化为安全有效的临床策略方面发挥核心作用，而该领域正在适应技术、治疗方法和地缘政治方面的压力。投资先进生物分析平台、扩展建模和模拟能力以及建立稳健供应链的供应商将更有能力满足学术机构、生物技术公司、合约研究组织 (CRO) 和大型製药企业的多样化需求。此外，区域趋势和关税相关因素凸显了灵活采购和近岸外包策略对于维持进度和资料品质的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 药物动力学服务市场：依类型划分

  • 聚合物药物动力学服务
  • 小分子药物动力学服务

第九章 药物动力学服务市场：依服务类型划分

  • In-Vitro
  • In-Vivo

第十章 药物动力学服务市场：依最终用户划分

  • 学术和政府附属研究机构
  • 生技公司
  • CRO（受託研究机构）
  • 製药公司

第十一章 药物动力学服务市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 药物动力学服务市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 药物动力学服务市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国：药物动力学服务市场

第十五章 中国：药物动力学服务市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Absorption Systems LLC
  • Allucent
  • Aurigene Pharmaceutical Services Ltd.
  • Certara
  • Charles River Laboratories, Inc.
  • Creative Bioarray
  • Eurofins Scientific SE
  • Evotec SE
  • Frontage Laboratories, Inc.
  • ICON PLC
  • Laboratory Corporation of America Holdings
  • LGC Limited by Cinven
  • NUVISAN Pharma Holding GmbH
  • Pacific BioLabs
  • Parexel International（MA）Corporation
  • Pfizer Inc.
  • PPD Inc. by Thermo Fisher Scientific Inc.
  • Premier Consulting
  • Reaction Biology Corporation
  • SGS SA
  • Svar Life Science AB
  • WuXi AppTec Co., Ltd.
  • XenoTech by BioIVT
  • Xyzagen
Product Code: MRR-C002B1C99681

The Pharmacokinetics Services Market was valued at USD 1.30 billion in 2025 and is projected to grow to USD 1.41 billion in 2026, with a CAGR of 9.34%, reaching USD 2.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.30 billion
Estimated Year [2026] USD 1.41 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 9.34%

Foundational overview describing the methodological backbone and strategic importance of pharmacokinetics services across modern drug development

Pharmacokinetics services are an integral pillar of contemporary drug discovery and development, providing the quantitative backbone that links molecular properties to clinical outcomes. This introduction frames pharmacokinetics as a multidisciplinary discipline that synthesizes analytical chemistry, bioanalysis, modeling, and in vivo experimentation to characterize absorption, distribution, metabolism, and excretion profiles. By establishing how therapeutic candidates behave in biological systems, pharmacokinetics guides dosing strategies, safety assessments, and translational decision-making across preclinical and clinical stages.

As regulatory expectations rise and therapeutic modalities diversify, pharmacokinetics laboratories have expanded capabilities to support both traditional small molecules and increasingly complex biologics. The convergence of advanced mass spectrometry, high-throughput bioanalytical workflows, and physiologically based pharmacokinetic modeling has improved the precision of exposure-response characterization. Consequently, organizational stakeholders-from bench scientists to program leads-depend on timely, reproducible pharmacokinetic data to de-risk portfolios, optimize trial design, and inform regulatory interactions. This section sets the stage for the deeper analyses that follow by highlighting the methodological foundations, cross-functional importance, and operational pressures shaping services in this sector.

Evolving technology, modality diversity, and regulatory expectations reshaping provider capabilities and collaborative scientific engagement

The pharmacokinetics services landscape is undergoing transformative shifts driven by technological advances, changing modality mixes, and evolving regulatory expectations. Innovations in bioanalytical instrumentation, including increased sensitivity in mass spectrometry and automation of sample processing, are shortening turnaround times and expanding the range of compounds that can be robustly quantified. At the same time, the rise of biologics, gene therapies, and nucleic acid medicines has compelled service providers to develop specialized assays and matrix handling capabilities that differ markedly from standard small molecule workflows.

Moreover, modeling and simulation techniques have matured into strategic decision-support tools. Physiologically based and population pharmacokinetic models are now routinely used to predict human pharmacokinetics from preclinical data, guide first-in-human dose selection, and simulate alternative dosing regimens. In parallel, regulatory agencies increasingly expect integrated PK/PD analyses and transparent modeling reports, prompting providers to embed regulatory-ready documentation into their deliverables. Together, these shifts are reshaping provider-client relationships, prompting deeper scientific collaboration and a focus on flexible, modular service offerings that can accommodate diverse therapeutic modalities and accelerated development timelines.

Operational resilience and procurement strategies becoming critical as tariff changes in 2025 introduce supply chain pressure and cross-border complexities

Changes to tariff policies and trade dynamics in the United States during 2025 have exerted a multifaceted influence on the pharmacokinetics services ecosystem, primarily through supply chain and cost-channel effects rather than direct scientific impact. Many service providers rely on imported raw materials, specialized reagents, and high-value instrumentation components; incremental tariff burdens on these inputs can elevate procurement complexity and prompt re-evaluation of sourcing strategies. In response, organizations may increase inventory buffers, qualify alternative suppliers, or shift to regional procurement networks to preserve operational continuity.

Beyond direct input costs, tariff-driven trade frictions can affect timelines for equipment maintenance, the availability of spare parts, and cross-border collaboration on sample transfers. Contract research organizations and analytical laboratories that operate transnationally may face additional customs documentation and potential delays, which in turn influence study timelines and client relationships. Importantly, these dynamics encourage greater attention to nearshoring and supplier diversification as resilience strategies. As a result, strategic procurement, contractual flexibility, and enhanced logistics planning have become priorities for stakeholders aiming to mitigate the operational consequences of tariff-related disruptions while maintaining the scientific rigor required for pharmacokinetic analyses.

Detailed segmentation-driven insights revealing distinct analytical requirements and delivery models across product types, service approaches, and client profiles

Segmentation analysis reveals distinct pathways for service development and client engagement across product types, service modalities, and end-user categories. Based on Type, market is studied across Large Molecules Pharmacokinetics Services and Small Molecules Pharmacokinetics Services, which highlights divergent analytical demands: large molecules require immunoassay development, ligand-binding assays, and specialized sample handling to address stability and matrix effects, whereas small molecules often leverage high-resolution mass spectrometry and validated chromatographic methods. Based on Service Type, market is studied across In-Vitro and In-Vivo, illustrating that in vitro ADME and stability assays complement in vivo pharmacokinetic studies by informing early candidate selection and mechanistic understanding of clearance pathways. Based on End-User, market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, demonstrating that client needs vary from exploratory, hypothesis-driven investigations to fully regulated GLP-compliant studies with comprehensive documentation for regulatory submissions.

Taken together, these segmentation dimensions emphasize that providers must offer modular service stacks that accommodate high-sensitivity analytics for biologics, throughput-focused platforms for small molecules, and end-user-specific deliverables. Academic and government research institutes often prioritize methodological flexibility and novel assay development, biotechnology companies require agility and scientific partnership, contract research organizations focus on scalable operations and compliance, and large pharmaceutical companies demand integrated program management and regulatory-grade reporting. This segmentation-driven perspective underscores the necessity for customizable workflows, robust quality systems, and adaptable commercial models to serve a heterogeneous client base effectively.

Regional competitive advantages and operational considerations determining where pharmacokinetics service providers invest, collaborate, and scale globally

Regional dynamics shape service provision, infrastructure investment, and collaborative networks across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each offering unique competitive advantages and operational considerations. In the Americas, dense concentrations of biotechnology hubs and clinical development centers support rapid translational workflows and close provider-client interactions, while regulatory pathways and payer environments influence the emphasis on clinical pharmacology and data packages for North American sponsors. In Europe, Middle East & Africa, the regulatory mosaic and strong academic-research linkages encourage cross-border collaborations, multi-center studies, and harmonized assay validation to meet diverse jurisdictional expectations.

The Asia-Pacific region has expanded analytical capacity, driven by investment in laboratory infrastructure and a growing base of contract research capability; this growth supports cost-effective execution of high-volume bioanalysis and increasingly sophisticated work in biologics. Across regions, logistical considerations, sample transfer regulations, and local talent pools inform decisions about study design and outsourcing. Therefore, effective regional strategies blend proximity to clients, regulatory expertise, and supply chain resilience to deliver consistent, high-quality pharmacokinetic services while enabling global program execution and knowledge transfer.

Competitive dynamics favor providers that integrate advanced analytics, cross-disciplinary expertise, and client-centric commercial models to drive long-term partnerships

Leading companies in the pharmacokinetics services arena are evolving beyond transactional assay delivery to provide integrated scientific partnerships that span bioanalysis, modeling, and regulatory support. Successful firms differentiate through investments in platform automation, data integrity systems, and cross-functional teams that translate analytical output into actionable pharmacokinetic and pharmacodynamic interpretations. Strategic collaborations with instrument manufacturers and software vendors enhance analytical sensitivity and throughput, while internal development of standardized reporting templates accelerates regulatory submissions and client decision-making.

Moreover, companies are investing in talent development-combining analytical chemists, clinical pharmacologists, and modelers-to offer end-to-end program support. Commercially, flexible pricing models, bundled service offerings, and capacity guarantees are being used to align with client risk profiles and development timelines. Providers that demonstrate consistent quality, transparent audit readiness, and the ability to scale from early discovery to regulated clinical studies are most likely to retain long-term partnerships. In sum, the competitive landscape rewards organizations that pair scientific depth with operational excellence and client-centric service design.

Practical strategic priorities for service providers to strengthen scientific capabilities, operational resilience, and client-aligned commercial frameworks

Industry leaders should prioritize actionable changes that strengthen scientific capability, commercial resilience, and client alignment in the near term. First, investing in platform automation and robust bioanalytical workflows can reduce turnaround times and improve reproducibility, which is essential for maintaining competitiveness as therapeutic modalities diversify. Second, expanding modeling and simulation expertise within service teams enables providers to offer predictive insights that inform dose selection and trial design, thereby adding strategic value to client programs.

Third, diversifying supply chains and qualifying multiple reagent and equipment vendors mitigates risks from trade disruptions and tariff-related impacts. Fourth, developing flexible contracting frameworks and value-based pricing can align incentives with clients, particularly for biotechnology companies and sponsorship models that require iterative program adjustments. Finally, enhancing regulatory support services-including documentation readiness and clear modeling reports-helps clients navigate multi-jurisdictional submission requirements. Collectively, these initiatives will improve operational resilience, deepen scientific engagement, and position providers as indispensable partners in increasingly complex drug development pathways.

Transparent multi-method research approach combining expert interviews, literature synthesis, and scenario analysis to validate pharmacokinetics service trends and implications

The research methodology underpinning this analysis integrates qualitative expert interviews, subject-matter literature review, and a structured assessment of technological and regulatory trends. Primary insights were derived from conversations with pharmacokinetic scientists, clinical pharmacologists, laboratory operations leaders, and procurement specialists, ensuring a multi-perspective understanding of capabilities and constraints. Secondary research included peer-reviewed publications, regulatory guidance documents, and recent technical white papers to capture advancements in bioanalytical instrumentation, modeling approaches, and assay validation practices.

Analytical synthesis emphasized cross-validation of themes across sources to identify consistent patterns rather than isolated observations. Where applicable, operational impacts were evaluated through scenario analysis to assess supply chain sensitivity and the implications of evolving regulatory expectations. Throughout, careful attention was paid to ensuring methodological transparency, documenting assumptions, and identifying areas where further empirical investigation would be valuable for specialized program planning or procurement decisions.

Concluding synthesis of strategic imperatives for providers to align scientific innovation, operational resilience, and client-focused delivery in pharmacokinetics services

In conclusion, pharmacokinetics services occupy a central role in translating molecular discovery into safe and efficacious clinical strategies, and the sector is adapting to technological, modality, and geopolitical pressures. Providers that invest in advanced bioanalytical platforms, expand modeling and simulation capabilities, and build resilient supply chains will be best positioned to meet the diverse needs of academic sponsors, biotechnology firms, contract research organizations, and large pharmaceutical companies. Furthermore, regional dynamics and tariff-related considerations underscore the importance of flexible sourcing and nearshoring strategies to preserve timelines and data quality.

Looking ahead, closer integration of analytical output with predictive modeling, regulatory-focused documentation, and client-centric contracting will define provider differentiation. By pursuing the actionable recommendations outlined earlier, stakeholders can reduce development risk, accelerate translational milestones, and align service delivery with strategic program objectives. Continued collaboration across scientific, operational, and commercial functions will be essential to sustain innovation and reliability within the pharmacokinetics services ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmacokinetics Services Market, by Type

  • 8.1. Large Molecules Pharmacokinetics Services
  • 8.2. Small Molecules Pharmacokinetics Services

9. Pharmacokinetics Services Market, by Service Type

  • 9.1. In-Vitro
  • 9.2. In-Vivo

10. Pharmacokinetics Services Market, by End-User

  • 10.1. Academic & Government Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Pharmacokinetics Services Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Pharmacokinetics Services Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pharmacokinetics Services Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Pharmacokinetics Services Market

15. China Pharmacokinetics Services Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Absorption Systems LLC
  • 16.6. Allucent
  • 16.7. Aurigene Pharmaceutical Services Ltd.
  • 16.8. Certara
  • 16.9. Charles River Laboratories, Inc.
  • 16.10. Creative Bioarray
  • 16.11. Eurofins Scientific SE
  • 16.12. Evotec SE
  • 16.13. Frontage Laboratories, Inc.
  • 16.14. ICON PLC
  • 16.15. Laboratory Corporation of America Holdings
  • 16.16. LGC Limited by Cinven
  • 16.17. NUVISAN Pharma Holding GmbH
  • 16.18. Pacific BioLabs
  • 16.19. Parexel International (MA) Corporation
  • 16.20. Pfizer Inc.
  • 16.21. PPD Inc. by Thermo Fisher Scientific Inc.
  • 16.22. Premier Consulting
  • 16.23. Reaction Biology Corporation
  • 16.24. SGS SA
  • 16.25. Svar Life Science AB
  • 16.26. WuXi AppTec Co., Ltd.
  • 16.27. XenoTech by BioIVT
  • 16.28. Xyzagen

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 31. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 34. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 38. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 42. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 43. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 46. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 50. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 54. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 67. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 75. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)